Back to Search
Start Over
Transcriptomic Profiling of Tumor-Infiltrating CD4 + TIM-3 + T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients.
- Source :
-
Vaccines [Vaccines (Basel)] 2020 Feb 06; Vol. 8 (1). Date of Electronic Publication: 2020 Feb 06. - Publication Year :
- 2020
-
Abstract
- T cell immunoglobulin mucin-3 (TIM-3) is an immune checkpoint identified as one of the key players in regulating T-cell responses. Studies have shown that TIM-3 is upregulated in the tumor microenvironment (TME). However, the precise role of TIM-3 in colorectal cancer (CRC) TME is yet to be elucidated. We performed phenotypic and molecular characterization of TIM-3 <superscript>+</superscript> T cells in the TME and circulation of CRC patients by analyzing tumor tissues (TT, TILs), normal tissues (NT, NILs), and peripheral blood mononuclear cells (PBMC). TIM-3 was upregulated on both CD4 <superscript>+</superscript> and CD3 <superscript>+</superscript> CD4 <superscript>-</superscript> (CD8 <superscript>+</superscript> ) TILs. CD4 <superscript>+</superscript> TIM-3 <superscript>+</superscript> TILs expressed higher levels of T regulatory cell (Tregs)-signature genes, including FoxP3 and Helios, compared with their TIM-3 <superscript>-</superscript> counterparts. Transcriptomic and ingenuity pathway analyses showed that TIM-3 potentially activates inflammatory and tumor metastatic pathways. Moreover, NF-κB-mediated transcription factors were upregulated in CD4 <superscript>+</superscript> TIM-3 <superscript>+</superscript> TILs, which could favor proliferation/invasion and induce inflammatory and T-cell exhaustion pathways. In addition, we found that CD4 <superscript>+</superscript> TIM-3 <superscript>+</superscript> TILs potentially support tumor invasion and metastasis, compared with conventional CD4 <superscript>+</superscript> CD25 <superscript>+</superscript> Tregs in the CRC TME. However, functional studies are warranted to support these findings. In conclusion, this study discloses some of the functional pathways of TIM-3 <superscript>+</superscript> TILs, which could improve their targeting in more specific therapeutic approaches in CRC patients.<br />Competing Interests: The authors declare no conflicts of interest.
Details
- Language :
- English
- ISSN :
- 2076-393X
- Volume :
- 8
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 32041340
- Full Text :
- https://doi.org/10.3390/vaccines8010071